02 · Clinical Findings
GLP-1s confer better glycemic, CV outcomes than metformin
A three year observational study of adults with prediabetes and obesity found lower rates of progression to type 2 diabetes and all cause mortality, though prospective trials are still needed.

In a three-year observational study of matched adults with prediabetes and obesity, GLP-1 receptor agonists outperformed standard metformin therapy.
Patients taking GLP-1 drugs returned to normal blood sugar more often (37.3% vs. 29.3%) and progressed to type 2 diabetes less frequently (25.1% vs. 37%). They also experienced lower rates of all-cause mortality and cardiovascular events like stroke and heart failure.
Because the TriNetX analysis relies on medical records, researchers stress the findings are preliminary and require prospective trials.
Read the full story at Healio Endocrinology ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years

Continue reading · Clinical FindingsPeptide News / Clinical FindingsGLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKDPharmacy Times · Oct 27, 2026 · scroll to read